Input 2020.12.11 06:00
Daewoong Pharmaceutical “Contribution to public quarantine by enabling self-treatment for mild patients”
Newgen, improved with’Napamostat’ pills that are injected for 24 hours
Clinical trials in 5 companies… “Let’s be the first” new competitors join–
–
According to the clinical portal of the Ministry of Food and Drug Safety (Drug Safety Nara) on the 11th, Daewoong Pharmaceutical, New Gen Therapeutics (subsidiary of New G Lab), Bukwang Pharmaceutical (003000)·Shinpoong Pharmaceutical (019170)Five domestic companies, including Crystal Genomics, are conducting clinical trials for oral treatments for Corona 19. It has been found that at least two companies are also conducting clinical trials, including All Bio and C&Pharm.
Among foreign companies, Merck Sharp & Dome (MSD) of the United States entered the 2/3 clinical trial of’MK-4482′, a candidate drug for corona treatment through a Korean subsidiary (MSD Korea) in October. MSD is undergoing global clinical trials not only in Korea.
Unlike injectables that can be treated only by visiting a hospital or hospitalized, edible drugs have the advantage that they are easy to take, so when marketed, both the marketability of the product and the public interest in the aspect of quarantine are evaluated to have an advantage over injections. There is also an expectation that the value of the oral treatment for Corona 19 will become more prominent in a situation where the risk of hospital infection has increased due to the relapse of Corona 19.
Originally taken medicines have the disadvantage that they can be decomposed by stomach acid, and the drug delivery ability is lower than that of injections. To overcome this, it takes more time and cost than injections in the development stage. This is the reason why the injection drug Celltrion’s antibody treatment and Green Cross’s blood system are the closest to domestic commercialization. Nevertheless, latecomers are expecting that drugs to be eaten will have greater competitiveness than injections, even if the market entry is delayed, considering that the pandemic (infectious disease pandemic) will be prolonged in a periodic fashion. In fact, the third corona19 epidemic is in progress in Korea.
An official of Daewoong Pharmaceutical said, “Consumers will choose the medicine that is easier to access from among the medicines to be eaten and injections.” I can,” he explained. Daewoong Pharmaceutical confirmed the efficacy of the COVID-19 treatment of Hoystar tablet (ingredient name Camostat), which is undergoing phase 2 clinical trials the day before, and emphasized that it is expected to become the first oral treatment for corona in Korea.
On the 3rd of last month, New Gen Therapeutics received approval for a phase 1 clinical trial for COVID-19 treatment of’New Gen Napamostat Tablet’, which replaced Napamostat, an injectable ingredient for pancreatitis treatment, into pills. Chong Kun Dang (185750)It is known that Napamostat, which is in phase 2 clinical trials, has a fast half-life (decomposition rate of drug components), so that it must be treated in a form suitable for 24 hours of infusion. Despite these inconveniences, the pancreatitis treatment market was small and it was difficult to develop it as a separate pill, but the situation has changed now that the potential as a treatment for Corona 19 has emerged.
Jae-seok Lim, CEO of New Gen Therapeutics, said, “Even if the Corona 19 vaccine is released, we believe that treatment will continue to be needed, and we are developing it as a medicine to be eaten like Tamiflu.” He emphasized, “We are proud that we are leading the way in researching medicines to eat when considering efficacy, etc.” Representative Lim said, “At the same price, people would prefer drugs to be eaten rather than injections.”
Some companies are preparing for new clinical trials. AllBio announced on the 7th that it is in consultation with a European Clinical Trial Commission (CRO) for domestic and international clinical promotion of an oral treatment for COVID-19 that combines with a natural drug delivery system that protects Napamostat from stomach acid. CEO Lee Jin-ha said, “As a latecomer, we plan to accelerate the R&D period as much as possible to develop and launch the world’s first oral treatment for Corona 19.”
C&Farm, a bio-venture company and a major shareholder of Hyundai Bioscience, announced on the 8th that it showed efficacy in treating Corona 19 by using niclosamide as a pill. Niclosamide is also a drug in clinical trials as an injection for the treatment of severely ill patients, and it has been known to be difficult to develop as a medicine to be eaten because it has high antiviral efficacy but is not absorbed by the body.
The development of oral treatments is forming a trend in the development of immunomodulators as well as COVID-19 treatments. NG Chem Life Science (183490)(2 phase), Jinwon Life Science (011000)(Phase 2) This is a typical clinical trial for an immunomodulatory drug that relieves inflammation such as pneumonia as an oral treatment.
–
– .
